Selling, General, and Administrative Costs: HUTCHMED (China) Limited vs Galapagos NV

SG&A Expenses: HUTCHMED vs Galapagos, 2014-2023

__timestampGalapagos NVHUTCHMED (China) Limited
Wednesday, January 1, 2014907900026684000
Thursday, January 1, 20152030900029829000
Friday, January 1, 20161694500039578000
Sunday, January 1, 20172055900043277000
Monday, January 1, 20182964100048645000
Tuesday, January 1, 20198825800052934000
Wednesday, January 1, 202016217000061349000
Friday, January 1, 2021167218000127125000
Saturday, January 1, 2022239528000136106000
Sunday, January 1, 202394252000133175999
Loading chart...

Igniting the spark of knowledge

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Selling, General, and Administrative (SG&A) expenses are a key indicator of a company's operational efficiency. This chart compares the SG&A expenses of HUTCHMED (China) Limited and Galapagos NV from 2014 to 2023.

Key Insights

  • Galapagos NV: From 2014 to 2023, Galapagos NV saw a dramatic increase in SG&A expenses, peaking in 2022 with a 2,500% rise from 2014. However, 2023 marked a significant reduction, dropping by 60% from the previous year.

  • HUTCHMED (China) Limited: This company experienced a steady increase in SG&A expenses, with a notable 400% rise from 2014 to 2023. The expenses peaked in 2022, showing a consistent upward trend.

These trends highlight the dynamic nature of financial management within the pharmaceutical sector, reflecting strategic shifts and market conditions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025